ICI 199441

structure given in first source; RN refers to (monohydrochloride, (S))-isomer; a potent & selective kappa agonist

Also Known As:

ICI 199,441; ICI-199441; N-(2-(N-methyl-3,4-dichlorophenylacetamido)-2-phenylethyl)pyrrolidine

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrrolidines: 115
    - ICI 199441: 2

Experts

1.	Maslov, L N: 2 articles (01/2021 - 10/2015)
2.	Mukhomedzyanov, A V: 2 articles (01/2021 - 10/2015)
3.	Khaliuli, I: 1 article (01/2021)
4.	Oeltgen, P R: 1 article (01/2021)
5.	Popov, S V: 1 article (01/2021)
6.	Prasad, N R: 1 article (01/2021)
7.	Tsibulnikov, S Y: 1 article (01/2021)
8.	Krylatov, A V: 1 article (10/2015)
9.	Lishmanov, Yu B: 1 article (10/2015)
10.	Tsibulnikov, S Yu: 1 article (10/2015)

Related Diseases

1.	Infarction (Infarctions) 01/01/2021 - "receptor antagonist TIPP[psi] and the selective opioid µ receptor antagonist CTAP did not alter the infarct reducing effect of (-)-U-50,488 and ICI 199,441. " 01/01/2021 - "Our study is the first to demonstrate the following: (a) the activation of opioid kappa2 receptor has no effect on cardiac tolerance to reperfusion; (b) peripheral opioid kappa1 receptor stimulation prevents reperfusion cardiac injury; (c) ICI 199,441 administration resulted in an infarct-reducing effect at reperfusion; (e) bradycardia induced by opioid kappa receptor antagonists is not dependent on the occupancy of opioid kappa receptor." 01/01/2021 - "Pretreatment with naltrexone, the peripherally acting opioid receptor antagonist naloxone methiodide, or the selective opioid kappa2 receptor antagonist nor-binaltorphimine completely abolished the infarct-reducing effect of (-)-U-50,488 and ICI 199,441. "
2.	Bradycardia 01/01/2021 - "Our study is the first to demonstrate the following: (a) the activation of opioid kappa2 receptor has no effect on cardiac tolerance to reperfusion; (b) peripheral opioid kappa1 receptor stimulation prevents reperfusion cardiac injury; (c) ICI 199,441 administration resulted in an infarct-reducing effect at reperfusion; (e) bradycardia induced by opioid kappa receptor antagonists is not dependent on the occupancy of opioid kappa receptor."
3.	Ischemia 10/01/2015 - "Administration of ICI 199,441 in a dose of 0.1 mg/kg 15 min before ischemia produced a potent antiarrhythmic effect. " 10/01/2015 - "Prospects of Using of κ-Opioid Receptor Agonists U-50,488 and ICI 199,441 for Improving Heart Resistance to Ischemia/Reperfusion."

Related Drugs and Biologics

1.	kappa Opioid Receptors (kappa Opioid Receptor)
2.	Opioid Analgesics (Opioids)
3.	Opioid Receptors (Opioid Receptor)
4.	Narcotic Antagonists (Opioid Antagonists)
5.	Naltrexone (ReVia)
6.	tyrosyl- tetrahydroisoquinolinecarbonyl- psi(methylamino)phenylalanyl- phenylalanine
7.	norbinaltorphimine
8.	N-methylnaloxone